Pamela Kunz, MD
Medical Oncologist
Leader of the Gastrointestinal Cancers Program at Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center
Director of GI Medical Oncology within the Section of Medical Oncology
New Haven, Connecticut
Dr. Pamela L. Kunz is the featured guest for CCF’s Luncheon with the Experts on Thursday, January 14, 2021. Dr. Kunz is Leader of the Gastrointestinal Cancers Program at Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center and Director of GI Medical Oncology within the Section of Medical Oncology. She serves on the Board of Directors for the North American Neuroendocrine Tumor Society (NANETS) and is Chairperson of the National Cancer Institute Neuroendocrine Tumor Task Force. Dr. Kunz is also a specialty editor in neuroendocrine tumors for cancer.net, doctor approved patient information from ASCO, the American Society of Clinical Oncology.
Prior to joining the team at Yale, Dr. Kunz was Director of the Neuroendocrine Tumor Program, Leader of the Endocrinology Oncology Research Group, and Director of the Neuroendocrine Tumor Fellowship at Stanford University School of Medicine,
Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine tumors (NETs) and is advancing the field through clinical trials and translational science that are defining the next generation of therapies for patients with this rare diagnosis.
Resources:
To read more and schedule appointments with Dr. Kunz, click here: https://medicine.yale.edu/profile/pamela_kunz/
Cancer.net:
https://www.cancer.net/cancer-types/neuroendocrine-tumors
https://www.cancer.net/cancer-types/neuroendocrine-tumor-gastrointestinal-tract
https://www.cancer.net/cancer-types/neuroendocrine-tumor-lung
https://www.cancer.net/cancer-types/neuroendocrine-tumor-pancreas
https://www.cancer.net/cancer-types/pheochromocytoma-and-paraganglioma
Selected Articles:
The Power of Trust, https://jamanetwork.com/journals/jamaoncology/article-abstract/2678964
North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253037/
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396396/
Surgery Versus Surveillance for Well?Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11 Year Analysis of the National Cancer Database, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011621/
Biologics in gastrointestinal and pancreatic neuroendocrine tumors, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506272/
Social Media:
Dr. Kunz on Twitter, @PamelaKunzMD
Yale Cancer Center on Twitter, @YaleCancer
